No Data
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
GuangYuYuan Chinese Herbal Medicine Co., Ltd.'s (SHSE:600771) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
GuangYuYuan Chinese Herbal Medicine (600771.SH): The largest Shareholder is proposed to change from Venture Capital to Hainan Shennong Technology Group.
On December 19, Gelonghui reported that GuangYuYuan Chinese Herbal Medicine (600771.SH) announced that its controlling shareholder, Hainan Shennong Technology Group Co., Ltd. (referred to as "Hainan Shennong Technology Group"), has signed a "Share Transfer Agreement between JinChuang Investment Co., Ltd. and Hainan Shennong Technology Group Co., Ltd. regarding GuangYuYuan Chinese Herbal Medicine Co., Ltd." JinChuang Investment intends to transfer its 71,508,968 shares in the company, accounting for 14.61% of the total share capital, to Hainan Shennong Technology Group through a non-public agreement, while also terminating the previous delegation of 14.6% of shares that JinChuang Investment entrusted Hainan Shennong Technology Group to exercise.
GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Investors Are up 5.0% in the Past Week, but Earnings Have Declined Over the Last Five Years
Guangyuyuan Traditional Chinese Medicine Co., Ltd. Report for the third quarter of 2024
Guangyuyuan Chinese Herbal Medicine (600771.SH) released its performance for the first three quarters, with a net income of 70.9642 million yuan, a year-on-year decrease of 22.49%.
guangyuyuan Chinese herbal medicine (600771.SH) disclosed the third quarter report of 2024, the company achieved revenue in the first three quarters...
GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Delivers Shareholders Respectable 11% CAGR Over 3 Years, Surging 7.0% in the Last Week Alone
